of honey. This publication teaches that a low molecular weight fraction from honey has generalised anti-inflammatory effects and no immune-stimulatory effects. It does not discuss specific anti-inflammatory action.

It will be appreciated from the above that it would be useful to provide alternative methods of treating inflammatory conditions, including inflammatory conditions associated with the gastrointestinal tract.

It is an object of the invention to provide methods of treating inflammatory conditions, including inflammatory conditions associated with the gastrointestinal tract and/or to address the foregoing problems or at least to provide the public with a useful choice.

Further aspects and advantages of the product, compositions methods and uses will become apparent from the ensuing description that is given by way of example only.

Summary ~~of the Invention~~

Described herein are compositions comprising 3,6,7-trimethyllumazine, and methods of using the same for preventing, ameliorating or treating MMP-9 associated conditions, inflammation of the gastrointestinal tract, and/or inflammatory conditions associated with gastrointestinal tract. The inventors have identified that a pteridine from honey, 3,6,7-trimethyllumazine, has anti-inflammatory activity and MMP-9 inhibitory activity. Being able to isolate the compound and characterise the anti-inflammatory and MMP-9 inhibitory activity provides the ability to produce medicaments for various uses including the treatment, prevention and amelioration of conditions associated with MMP-9, including inflammatory conditions of the gastrointestinal tract.

In one aspect, the present disclosure provides a use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating an MMP-9 associated condition.

In a first particular ~~aspect~~example, the present ~~invention~~ disclosure provides a method of preventing, ameliorating or treating an MMP-9 associated condition in a subject, comprising administering to a subject in need thereof a composition comprising 3,6,7-trimethyllumazine.

In one ~~embodiment~~ example~~of the first aspect~~, the MMP-9 associated condition is selected from gastrointestinal inflammatory diseases, gastric ulcers (for example peptic ulcers), gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome (IBS), digestive diseases, Gastroesophageal Reflux Disease (GERD), heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis, esophageal ulcers, neuropsychiatric illnesses (such as schizophrenia, bipolar mood disorder, multiple

sclerosis), neurodegenerative disorders (such as traumatic brain injury, multiple sclerosis, and Alzheimer's disease), cardiovascular diseases, cancer and arthritis.

In a second particular ~~aspect~~example, the ~~invention~~ disclosure provides a method of preventing, ameliorating or treating an MMP-9 associated inflammatory condition in a subject, comprising administering to a subject in need thereof a composition comprising 3,6,7-trimethyllumazine.

In one example~~embodiment of the second aspect~~, the MMP-9 associated inflammatory condition is associated with inflammation of the gastrointestinal tract. In another example~~embodiment~~, the MMP-9 associated inflammatory condition is selected from, gastrointestinal inflammatory diseases, gastric ulcers (for example peptic ulcers), gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome (IBS), digestive diseases, Gastroesophageal Reflux Disease (GERD), heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis and/or esophageal ulcers.

In one example~~embodiment~~, the MMP-9 associated inflammatory condition is selected from neuropsychiatric illnesses (such as schizophrenia, bipolar mood disorder, multiple sclerosis), neurodegenerative disorders (such as traumatic brain injury, multiple sclerosis, and Alzheimer's disease), cardiovascular diseases, cancer and arthritis.

In a third particular example~~aspect~~, the disclosure ~~invention~~ provides a method of preventing, ameliorating or treating inflammation in a subject comprising administering to a subject in need thereof a composition comprising 3,6,7-trimethyllumazine.

In one example~~embodiment of the third particular aspect~~, the inflammation is associated with the gastrointestinal tract of a subject. In one example~~embodiment~~, the inflammation is associated with conditions selected from: gastrointestinal inflammatory diseases, gastric ulcers (for example peptic ulcers), gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome (IBS), digestive diseases, Gastroesophageal Reflux Disease (GERD), heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis, esophageal ulcers, neuropsychiatric illnesses (such as schizophrenia, bipolar mood disorder, multiple sclerosis), neurodegenerative disorders (such as traumatic brain injury, multiple sclerosis, and Alzheimer's disease), cardiovascular diseases, cancer and/or arthritis.

In one example~~embodiment of aspects one to three~~, the origin of the 3,6,7-trimethyllumazine is from *Leptospermum*. In one example~~embodiment~~, the 3,6,7-trimethyllumazine is substantially

from plants selected from the group comprising: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and combinations thereof. In one exampleembodiment, the 3,6,7-trimethyllumazine is from *Leptospermum scoparium*.

In one exampleembodiment of aspects one to three, the origin of the 3,6,7-trimethyllumazine is honey.

In one exampleembodiment, the honey is of a floral origin substantially from the genus *Leptospermum*. In one exampleembodiment, the honey is of a floral origin substantially from: *Leptospermum scoparium*, *Leptospermum polygalifolium*, *Leptospermum subtenue*, and/or combinations thereof. In one exampleembodiment, the honey is of a floral origin substantially from *Leptospermum scoparium* (also referred to as Manuka).

In one exampleembodiment of aspects one to three, the 3,6,7-trimethyllumazine is derived directly from a plant of the genus *Leptospermum*. In one exampleembodiment, the 3,6,7-trimethyllumazine is derived directly from the flowers, nectar, roots, fruit, seeds, bark, oil, leaves, wood, stems or other plant material of a plant of the genus *Leptospermum*. In one exampleembodiment, the 3,6,7-trimethyllumazine is substantially from plants selected from the group comprising: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and combinations thereof.

In one exampleembodiment of the above aspects, the composition comprising 3,6,7-trimethyllumazine comprises honey. In one exampleembodiment, the composition comprising 3,6,7-trimethyllumazine consists of honey.

In one exampleembodiment of the above aspects, the composition comprising 3,6,7-trimethyllumazine comprises of a honey extract. In one exampleembodiment of the above aspects, the composition comprising 3,6,7-trimethyllumazine comprises a honey extract, wherein the honey extract comprises a concentration of 3,6,7-trimethyllumazine that is higher than the concentration of 3,6,7-trimethyllumazine found naturally occurring in honey. In one exampleembodiment, the composition consists of a honey extract, wherein the honey extract comprises a concentration of 3,6,7-trimethyllumazine that is higher than the concentration of 3,6,7-trimethyllumazine found naturally occurring in honey. In one exampleembodiment, the honey extract comprises a concentration of 3,6,7-trimethyllumazine that is higher than the concentration of 3,6,7-trimethyllumazine found naturally occurring in the honey from which the extract was derived.

In one exampleembodiment, the honey from which the extract is derived is of a floral origin substantially from the genus *Leptospermum*. In one exampleembodiment, the honey from

which the extract is derived is of a floral origin substantially from a genus selected from: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and combinations thereof. In one exampleembodiment, the composition further comprises honey.

In one exampleembodiment of the above aspects, the honey is raw honey, heat-treated honey or pasteurised honey.

In one exampleembodiment of the above aspects, the composition comprises 3,6,7-trimethyllumazine isolated from honey. In one exampleembodiment, the honey is of a floral origin substantially from the genus *Leptospermum*. In one exampleembodiment, the honey is of a floral origin substantially from the genus: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and/or combinations thereof. In one exampleembodiment, the 3,6,7-trimethyllumazine is isolated by subjection of the honey to solid phase extraction, followed by normal-phase flash chromatography and preparative thin layer chromatography.

In one exampleembodiment of the above aspects, the 3,6,7-trimethyllumazine is synthetic. In one exampleembodiment, the composition further comprises honey.

In one exampleembodiment, the composition comprises from about 2.5 µg/mL to about 1000 µg/mL 3,6,7-trimethyllumazine. In one exampleembodiment, the composition comprises 3,6,7-trimethyllumazine from about 2.5 µg/mL, about 5 µg/mL, about 10 µg/mL, about 20 µg/mL, about 40 µg/mL, about 50 µg/mL, about 60 µg/mL, about 70 µg/mL, about 80 µg/mL, about 90 µg/mL, about 100 µg/mL, 150 µg/mL, about 200 µg/mL, about 250 µg/mL, about 300 µg/mL, about 350 µg/mL, about 400 µg/mL, about 450 about 500 µg/mL, about 550 µg/mL, about 600 µg/mL, about 650 µg/mL, about 700 µg/mL, about 750 µg/mL, about 800 µg/mL, about 850 µg/mL, about 900 µg/mL, about 950 µg/mL, to about 1000 µg/mL, or wherein the composition comprises 3,6,7-trimethyllumazine from about 2.5 to 5 µg/mL, about 5 to 10 µg/mL, about 10 to 20 µg/mL, about 20 to 40 µg/mL, about 40 to 50 µg/mL, about 50 to 60 µg/mL, about 60 to 70 µg/mL, about 70 to 80 µg/mL, about 80 to 90 µg/mL, about 90 to 100 µg/mL, about 100 to 150 µg/mL, 150 to 200 µg/mL, about 200 to 250 µg/mL, about 250 to 300 µg/mL, about 300 to 350 µg/mL, about 350 to 400 µg/mL, about 400 to 450 µg/mL, about 450 to 500 µg/mL, about 500 to 550 µg/mL, about 550 to 600 µg/mL, about 600 to 650 µg/mL, about 650 to 700 µg/mL, about 700 to 750 µg/mL, about 750 to 800 µg/mL, about 800 to 850 µg/mL, about 850 to 900 µg/mL, about 900 to 950 µg/mL, about 950 to 1000 µg/mL.

In one exampleembodiment, the composition comprises 3,6,7-trimethyllumazine from about 5 mg/kg to about 3000 mg/kg. In one exampleembodiment, the composition comprises 3,6,7-

trimethyllumazine from about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, about 100 mg/kg, about 150 mg/kg, about 200 mg/kg, about 250 mg/kg, about 300mg/kg, about 350 mg/kg, about 400 mg/kg, about 450 mg/kg, about 500 mg/kg, about 550 mg/kg, about 600 mg/kg, about 650 mg/kg, about 700 mg/kg, about 750 mg/kg, about 800 mg/kg, about 850 mg/kg, about 900 mg/kg, about 950 mg/kg, about 1000 mg/kg, about 1100 mg/kg, about 1200 mg/kg, about 1300 mg/kg, about 1400 mg/kg, about 1500 mg/kg, about 1600 mg/kg, about 1700 mg/kg, about 1800 mg/kg, about 1900 mg/kg, about 2000 mg/kg, about 2100 mg/kg, about 2200 mg/kg, about 2300 mg/kg, about 2400 mg/kg, about 2500 mg/kg, about 2600 mg/kg, about 2700 mg/kg, about 2800 mg/kg, about 2900 mg/kg to about 3000 mg/kg or wherein the composition comprises a concentration of 3,6,7-trimethyllumazine of from 5 to 10 mg/kg, or from 10 to 15 mg/kg, or from 15 to 20 mg/kg, or from 20 to 25 mg/kg, or from 25 to 30 mg/kg, or from 30 to 35 mg/kg, or from 35 to 40 mg/kg, or form 40 to 45 mg/kg, or from 45 to 50 mg/kg, or from 50 to 55 mg/kg, or from 55 to 60 mg/kg, or from 60 70 mg/kg or from 70 to 80 mg/kg, about 90 to 100 mg/kg, about 100 to 150 mg/kg, about 150 to 200 mg/kg, about 200 mg/kg, about 250 to 300 mg/kg, about 300 to 350 mg/kg, about 350 to 400 mg/kg, about 400 to 450 mg/kg, about 450 to 500 mg/kg, about 500 to 550 mg/kg, about 550 to 600 mg/kg, about 600 to 650 mg/kg, about 650 to 700 mg/kg, about 700 to 750 mg/kg, about 750 to 800 mg/kg, about 800 to 850 mg/kg, about 850 to 900 mg/kg, about 900 to 950 mg/kg, about 950 to 1000 mg/kg, about 1000 to 1100 mg/kg, about 1100 to 1200 mg/kg, about 1200 to 1300 mg/kg, about 1300 to 1400 mg/kg, about 1400 to 1500 mg/kg, about 1500 to 1600 mg/kg, about 1600 to 1700 mg/kg, about 1700 to 1800 mg/kg, about 1800 to 1900 mg/kg, about 1900 to 2000 mg/kg, about 2000 to 2100 mg/kg, about 2100 to 2200 mg/kg, about 2200 to 2300 mg/kg, about 2300 to 2400 mg/kg, about 2400 to 2500 mg/kg, about 2500 to 2600 mg/kg, about 2600 to 2700 mg/kg, about 2700 to 2800 mg/kg, about 2800 to 2900 mg/kg, about 2900 to 3000 mg/kg.

In one example~~embodiment of the above aspects~~, the composition comprises a therapeutically effective amount of 3,6,7-trimethyllumazine.

In one example~~embodiment~~, the composition comprising 3,6,7-trimethyllumazine is formulated as a medicament, therapeutic product or health supplement. In one example~~embodiment~~, the composition comprising 3,6,7-trimethyllumazine is formulated into a range of delivery systems, including but not limited to, liquid formulations, capsules, chewable tablet, tablets, suppositories, fast moving consumer goods, intravenous preparations,

intramuscular preparations, subcutaneous preparations, solutions, food, beverages, dietary supplements, cosmetic formulation, gels, lotions, powders or sprays.

In one exampleembodiment of the above aspects, the method comprises administering the composition comprising 3,6,7-trimethyllumazine one, two, three, four or five times daily.

In one exampleembodiment of the above aspects, the method comprises administering the composition comprising 3,6,7-trimethyllumazine one, two, three, four, five, six or seven times weekly.

In one exampleembodiment, the composition comprising 3,6,7-trimethyllumazine is administered as a single dose or as a divided dose. In one exampleembodiment, the composition comprising 3,6,7-trimethyllumazine is administered as one, two three or four separate doses.

In one exampleembodiment of the above aspects, the method comprises administration of the composition comprising 3,6,7-trimethyllumazine at a dose from about 1mg to about 3000mg. In one particular exampleembodiment, the method comprises administration of the composition comprising from about 1mg, 10mg, 20mg, 30mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100mg, 150 mg, 200mg, 250 mg, 300mg, 350mg, 400mg, 450 mg, 500mg, 550 mg, 600mg, 650mg, 700mg, 750 mg, 800mg, 850 mg, 900mg, 950 mg, 1000mg, 1100mg, 1200mg, 1300mg, 1400mg, 1500mg, 1600mg, 1700mg, 1800mg, 1900mg, 2000mg, 2100mg, 2200mg, 2300mg, 2400mg, 2500mg, 2600mg, 2700mg, 2800mg, 2900mg, 3000mg 3,6,7-trimethyllumazine.

In one exampleembodiment of the above aspects, the method comprises administering the composition at a dose of from about 5g to about 100g 3,6,7-trimethyllumazine.

In one exampleembodiment of the above aspects, the composition comprising 3,6,7-trimethyllumazine has a standardised concentration of 3,6,7-trimethyllumazine obtained by:

- selecting a first composition with a known concentration of 3,6,7-trimethyllumazine;
- selecting at least one further composition with a known concentration of 3,6,7-trimethyllumazine;
- combining the first composition with the second composition to obtain a final composition with a standardised 3,6,7-trimethyllumazine concentration of from about 5 mg/kg to about 3000 mg/kg.

In one exampleembodiment of the above aspects, the composition comprising 3,6,7-

trimethyllumazine has a standardised concentration of 3,6,7-trimethyllumazine obtained by:

- selecting a first composition with a known concentration of 3,6,7-trimethyllumazine;
- combining the selected first composition with one or more of:
  - synthetic 3,6,7-trimethyllumazine;
  - isolated 3,6,7-trimethyllumazine;
  - a honey extract comprising 3,6,7-trimethyllumazine; and/or
  - 3,6,7-trimethyllumazine derived directly from a plant of the genus *Leptospermum*;

to form a composition with a standardised 3,6,7-trimethyllumazine concentration of from about 5 mg/kg to about 3000 mg/kg.

In one example~~embodiment~~, the composition comprises honey, a honey extract, isolated 3,6,7-trimethyllumazine and/or synthetic 3,6,7-trimethyllumazine.

In one example~~embodiment~~, the 3,6,7-trimethyllumazine derived directly from a plant is derived directly from the flowers, nectar, roots, fruit, seeds, bark, oil, leaves, wood, stems or other plant material of a plant of the genus *Leptospermum*.

In one example~~embodiment~~, the standardised 3,6,7-trimethyllumazine concentration is from about 5 mg/kg to about 3000 mg/kg. In one example~~embodiment~~, the standardised 3,6,7-trimethyllumazine concentration is from: about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, about 100 mg/kg, about 150 mg/kg, about 200 mg/kg, about 250 mg/kg, about 300mg/kg, about 350 mg/kg, about 400 mg/kg, about 450 mg/kg, about 500 mg/kg, about 550 mg/kg, about 600 mg/kg, about 650 mg/kg, about 700 mg/kg, about 750 mg/kg, about 800 mg/kg, about 850 mg/kg, about 900 mg/kg, about 950 mg/kg, about 1000 mg/kg, about 1100 mg/kg, about 1200 mg/kg, about 1300 mg/kg, about 1400 mg/kg, about 1500 mg/kg, about 1600 mg/kg, about 1700 mg/kg, about 1800 mg/kg, about 1900 mg/kg, about 2000 mg/kg, about 2100 mg/kg, about 2200 mg/kg, about 2300 mg/kg, about 2400 mg/kg, about 2500 mg/kg, about 2600 mg/kg, about 2700 mg/kg, about 2800 mg/kg, about 2900 mg/kg to about 3000 mg/kg of 3,6,7-trimethyllumazine.

In one example~~embodiment~~, the concentration of the 3,6,7-trimethyllumazine is determined by chromatography, analytical measurements, spectrophotometry and/or any other method known to a person skilled in the art. In one example~~embodiment~~, the concentration of 3,6,7-

trimethyllumazineis determined by reverse-phase HPLC system.

In a fourth particular ~~aspect~~ example the disclosure ~~invention~~ provides a method of making a composition with anti-inflammatory and/or MMP-9 inhibitory activity comprising:

a. testing a first composition comprising honey for 3,6,7-trimethyllumazine concentration;
b. testing at least one further composition comprising honey for 3,6,7-trimethyllumazine concentration;
c. selecting a composition comprising honey with a 3,6,7-trimethyllumazine concentration greater than from about 5 mg/kg 3,6,7-trimethyllumazine;
d. selecting at least one further composition comprising honey with a 3,6,7-trimethyllumazine concentration greater than about 5 mg/kg;
e. combining the selected composition comprising honey to form a honey composition with a 3,6,7-trimethyllumazine concentration of at least from about 5 to about 80 mg/kg.

In another aspect, the disclosure provides a method of making a composition with anti-inflammatory and/or MMP-9 inhibitory activity comprising:

a. testing a first composition comprising honey for 3,6,7-trimethyllumazine concentration;
b. testing at least one further composition comprising honey for 3,6,7-trimethyllumazine concentration;
c. selecting a composition comprising honey with a 3,6,7-trimethyllumazine concentration greater than about 5 mg/kg;
d. selecting at least one further composition comprising honey with a 3,6,7-trimethyllumazine concentration greater than from about 5 mg/kg 3,6,7-trimethyllumazine;
e. combining the selected composition comprising honey to form a honey composition with a 3,6,7-trimethyllumazine concentration of at least from about 5 to about 80 mg/kg,

optionally wherein the composition comprising honey is selected if it has a concentration of 3,6,7-trimethyllumazine greater than about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg or about 80 mg/kg.

In one example~~embodiment of the fourth aspect~~, the composition comprising honey is selected if it has a concentration of 3,6,7-trimethyllumazine greater than about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70

mg/kg or about 80 mg/kg.

In one example~~embodiment of the fourth aspect~~, the composition is honey.

In one example~~embodiment~~, the 3,6,7-trimethyllumazine concentration is determined by chromatography, analytical measurements, spectrophotometry and/or any other method known to a person skilled in the art. In one example~~embodiment~~, the concentration of 3,6,7-trimethyllumazineis determined by reverse-phase HPLC system.

In one example~~embodiment of the fourth aspect~~, the composition with anti-inflammatory activity is suitable for use in the method of any one of ~~aspects~~ examples one to three.

In a fifth particular example, ~~aspect~~ the disclosure ~~invention~~ provides a method of identifying a composition as having anti-inflammatory and/or MMP-9 inhibitory activity comprising:

a. testing a composition for 3,6,7-trimethyllumazine concentration; and
    i. identifying the composition as having anti-inflammatory and/or MMP-9 inhibitory activity if it contains a 3,6,7-trimethyllumazine concentration greater than from about 5 mg/kg; or

ii. identifying the composition as not having anti-inflammatory and/or MMP-9 inhibitory activity if it contains a 3,6,7-trimethyllumazine concentration lower than from about 5 mg/kg.

In another aspect, the disclosure provides a method of identifying a composition as having anti-inflammatory and/or MMP-9 inhibitory activity comprising:

a. testing a composition for 3,6,7-trimethyllumazine concentration; and

i. identifying the composition as having anti-inflammatory and/or MMP-9 inhibitory activity if it contains a 3,6,7-trimethyllumazine concentration greater than from about 5 mg/kg; or

ii. identifying the composition as not having anti-inflammatory and/or MMP-9 inhibitory activity if it contains a 3,6,7-trimethyllumazine concentration lower than from about 5 mg/kg,

optionally wherein the composition comprises honey.

In one example~~embodiment~~, the composition comprises honey or a honey extract.

In one example~~embodiment of the fifth particular aspect~~, the composition comprising honey is determined as having anti-inflammatory activity if it contains greater than about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg or about 80 mg/kg.

In one example~~embodiment of the fifth aspect~~, the composition is honey or a honey extract.

In one example~~embodiment of the fifth particular aspect~~, the composition with anti-inflammatory activity is suitable for use in any one of examples ~~aspects~~ one to three.

In a sixth particular example~~aspect~~, the disclosure ~~invention~~ provides a method of identifying a composition with anti-inflammatory and/or MMP-9 inhibitory activity suitable for use in a method of any of examples ~~aspects~~ one to three, comprising:

a. testing a composition for 3,6,7-trimethyllumazine concentration; and

i. identifying the composition as suitable for use in any of examples ~~aspects~~ one to three if it contains a 3,6,7-trimethyllumazine concentration greater than from about 5 to about 80 mg/kg 3,6,7-trimethyllumazine; or

ii. identifying the composition as not suitable for use in any of examples ~~aspects~~ one to three if it contains a 3,6,7-trimethyllumazine concentration lower than from about 5 mg/kg 3,6,7-trimethyllumazine.

In one example~~embodiment of the sixth particular aspect~~, the composition is identified as suitable for use in a method of any one of examples ~~aspects~~ one to four if it contains a 3,6,7-trimethyllumazine concentration greater than about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg or about 80 mg/kg.

In one example~~embodiment~~, the composition is honey or a honey extract.

In one example~~embodiment~~, the 3,6,7-trimethyllumazine concentration is determined by

chromatography, analytical measurements, spectrophotometry and/or any other method known to a person skilled in the art. In one exampleembodiment, the concentration of 3,6,7-trimethyllumazineis determined by reverse-phase HPLC system.

In a seventh particular exampleaspect, the disclosure invention provides a composition comprising 3,6,7-trimethyllumazine suitable for use in the method of any of the above examplesaspects.

In one exampleembodiment of the seventh aspect, the origin of the 3,6,7-trimethyllumazine is from *Leptospermum*. In one exampleembodiment, the 3,6,7-trimethyllumazine is substantially from plants selected from the group comprising: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and combinations thereof. In one exampleembodiment, the 3,6,7-trimethyllumazine is from *Leptospermum scoparium*.

In one exampleembodiment of the seventh aspect, the origin of the 3,6,7-trimethyllumazine is honey. In one exampleembodiment, the honey is of a floral origin substantially from the genus *Leptospermum*. In one exampleembodiment, the honey is of a floral origin substantially from: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and/or combinations thereof. In one exampleembodiment, the honey is of a floral origin substantially from *Leptospermum scoparium* (Manuka).

In one exampleembodiment of the seventh aspect, the 3,6,7-trimethyllumazine is derived directly from a plant of the genus *Leptospermum*. In one exampleembodiment, the 3,6,7-trimethyllumazine is derived directly from the nectar, roots, fruit, seeds, bark, oil, leaves, wood, stems or other plant material of a plant of the genus *Leptospermum*. In one exampleembodiment, the 3,6,7-trimethyllumazine is substantially from plants selected from the group comprising: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and combinations thereof.

In one exampleembodiment of the seventh aspect, the composition comprising 3,6,7-trimethyllumazine comprises honey. In one exampleembodiment, the composition comprising 3,6,7-trimethyllumazine consists of honey.

In one exampleembodiment of the above aspects, the composition comprising 3,6,7-trimethyllumazine comprises of a honey extract. In one exampleembodiment =, the composition comprising 3,6,7-trimethyllumazine comprises a honey extract, wherein the honey extract comprises a concentration of 3,6,7-trimethyllumazine that is higher than the concentration of 3,6,7-trimethyllumazine found naturally occurring in honey. In one exampleembodiment, the composition consists of a honey extract, wherein the honey extract comprises a concentration of 3,6,7-trimethyllumazine that is higher than the concentration of 3,6,7-trimethyllumazine found naturally occurring in honey. In one

exampleembodiment, the honey extract comprises a concentration of 3,6,7-trimethyllumazine that is higher than the concentration of 3,6,7-trimethyllumazine found naturally occurring in the honey from which the extract was derived.

In one exampleembodiment, the honey from which the extract is derived is of a floral origin substantially from the genus *Leptospermum*. In one exampleembodiment, the honey from which the extract is derived is of a floral origin substantially from a genus selected from: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and combinations thereof. In one exampleembodiment, the composition further comprises honey.

In one exampleembodiment, the honey is raw honey, heat-treated honey or pasteurised honey.

In one exampleembodiment, the composition comprises 3,6,7-trimethyllumazine isolated from honey. In one exampleembodiment, the honey is of a floral origin substantially from the genus *Leptospermum*. In one exampleembodiment, the honey is of a floral origin substantially from the genus: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and/or combinations thereof. In one exampleembodiment, the 3,6,7-trimethyllumazine is isolated by subjection of the honey to solid phase extraction, followed by normal-phase flash chromatography and preparative thin layer chromatography.

In one exampleembodiment, the composition comprises synthetic 3,6,7-trimethyllumazine. In one exampleembodiment, the composition further comprises honey.

In one exampleembodiment, the composition comprises from about 2.5 µg/mL to about 1000 µg/mL 3,6,7-trimethyllumazine. In one exampleembodiment, the composition comprises from about 2.5 µg/mL, about 5 µg/mL, about 10 µg/mL, about 20 µg/mL, about 40 µg/mL, about 50 µg/mL, about 60 µg/mL, about 70 µg/mL, about 80 µg/mL, about 90 µg/mL, about 100 µg/mL, 150 µg/mL, about 200 µg/mL, about 250 µg/mL, about 300 µg/mL, about 350 µg/mL, about 400 µg/mL, about 450 about 500 µg/mL, about 550 µg/mL, about 600 µg/mL, about 650 µg/mL, about 700 µg/mL, about 750 µg/mL, about 800 µg/mL, about 850 µg/mL, about 900 µg/mL, about 950 µg/mL, to about 1000 µg/mL 3,6,7-trimethyllumazine, or wherein the composition comprises from about 2.5 to 5 µg/mL, about 5 to 10 µg/mL, about 10 to 20 µg/mL, about 20 to 40 µg/mL, about 40 to 50 µg/mL, about 50 to 60 µg/mL, about 60 to 70 µg/mL, about 70 to 80 µg/mL, about 80 to 90 µg/mL, about 90 to 100 µg/mL, about 100 to 150 µg/mL, 150 to 200 µg/mL, about 200 to 250 µg/mL, about 250 to 300 µg/mL, about 300 to 350 µg/mL, about 350 to 400 µg/mL, about 400 to 450 µg/mL, about 450 to 500 µg/mL, about 500 to 550 µg/mL, about 550 to 600 µg/mL, about 600 to 650 µg/mL, about 650 to 700 µg/mL,

about 700 to 750 µg/mL, about 750 to 800 µg/mL, about 800 to 850 µg/mL, about 850 to 900 µg/mL, about 900 to 950 µg/mL, about 950 to 1000 µg/mL 3,6,7-trimethyllumazine.

In one exampleembodiment, the composition comprises 3,6,7-trimethyllumazine from about 5 mg/kg to about 3000 mg/kg 3,6,7-trimethyllumazine. In one exampleembodiment, the composition comprises 3,6,7-trimethyllumazine from about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, about 100 mg/kg, about 150 mg/kg, about 200 mg/kg, about 250 mg/kg, about 300mg/kg, about 350 mg/kg, about 400 mg/kg, about 450 mg/kg, about 500 mg/kg, about 550 mg/kg, about 600 mg/kg, about 650 mg/kg, about 700 mg/kg, about 750 mg/kg, about 800 mg/kg, about 850 mg/kg, about 900 mg/kg, about 950 mg/kg, about 1000 mg/kg, about 1100 mg/kg, about 1200 mg/kg, about 1300 mg/kg, about 1400 mg/kg, about 1500 mg/kg, about 1600 mg/kg, about 1700 mg/kg, about 1800 mg/kg, about 1900 mg/kg, about 2000 mg/kg, about 2100 mg/kg, about 2200 mg/kg, about 2300 mg/kg, about 2400 mg/kg, about 2500 mg/kg, about 2600 mg/kg, about 2700 mg/kg, about 2800 mg/kg, about 2900 mg/kg to about 3000 mg/kg or wherein the composition comprises a concentration of 3,6,7-trimethyllumazine of 5 to 10 mg/kg, or from 10 to 15 mg/kg, or from 15 to 20 mg/kg, or from 20 to 25 mg/kg, or from 25 to 30 mg/kg, or from 30 to 35 mg/kg, or from 35 to 40 mg/kg, or form 40 to 45 mg/kg, or from 45 to 50 mg/kg, or from 50 to 55 mg/kg, or from 55 to 60 mg/kg, or from 60 70 mg/kg or from 70 to 80 mg/kg, about 90 to 100 mg/kg, about 100 to 150 mg/kg, about 150 to 200 mg/kg, about 200 mg/kg, about 250 to 300 mg/kg, about 300 to 350 mg/kg, about 350 to 400 mg/kg, about 400 to 450 mg/kg, about 450 to 500 mg/kg, about 500 to 550 mg/kg, about 550 to 600 mg/kg, about 600 to 650 mg/kg, about 650 to 700 mg/kg, about 700 to 750 mg/kg, about 750 to 800 mg/kg, about 800 to 850 mg/kg, about 850 to 900 mg/kg, about 900 to 950 mg/kg, about 950 to 1000 mg/kg, about 1000 to 1100 mg/kg, about 1100 to 1200 mg/kg, about 1200 to 1300 mg/kg, about 1300 to 1400 mg/kg, about 1400 to 1500 mg/kg, about 1500 to 1600 mg/kg, about 1600 to 1700 mg/kg, about 1700 to 1800 mg/kg, about 1800 to 1900 mg/kg, about 1900 to 2000 mg/kg, about 2000 to 2100 mg/kg, about 2100 to 2200 mg/kg, about 2200 to 2300 mg/kg, about 2300 to 2400 mg/kg, about 2400 to 2500 mg/kg, about 2500 to 2600 mg/kg, about 2600 to 2700 mg/kg, about 2700 to 2800 mg/kg, about 2800 to 2900 mg/kg, about 2900 to 3000 mg/kg.

In one exampleembodiment, the composition comprises a therapeutically effective amount of 3,6,7-trimethyllumazine.

In one exampleembodiment, the composition comprising 3,6,7-trimethyllumazine is formulated as a medicament, therapeutic product or health supplement. In one exampleembodiment, the composition comprising 3,6,7-trimethyllumazine is formulated into a range of delivery systems, including but not limited to, liquid formulations, fast moving consumer goods, capsules, chewable tablet, tablets, suppositories, intravenous preparations, intramuscular preparations, subcutaneous preparations, solutions, food, beverages, dietary supplements, cosmetic formulations, gels, lotions, powders or sprays.

In an eighth particular exampleaspect, the present disclosure invention provides a use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating an MMP-9 associated condition in a subject.

In one exampleembodiment of the eighth aspect, the MMP-9 associated condition is selected from gastrointestinal inflammatory diseases, gastric ulcers (for example peptic ulcers), gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome (IBS), digestive diseases, Gastroesophageal Reflux Disease (GERD), heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis,esophageal ulcers, neuropsychiatric illnesses (such as schizophrenia, bipolar mood disorder, multiple sclerosis), neurodegenerative disorders (such as traumatic brain injury, multiple sclerosis, and Alzheimer's disease), cardiovascular diseases, cancer and arthritis.

In a ninth particular exampleaspect, the disclosure invention provides a use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating an MMP-9 associated inflammatory condition in a subject.

In one exampleembodiment of the ninth aspect, the MMP-9 associated inflammatory condition is associated with inflammation of the gastrointestinal tract. In another exampleembodiment, the MMP-9 associated inflammatory condition is selected from, gastrointestinal inflammatory diseases, gastric ulcers (for example peptic ulcers), gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome (IBS), digestive diseases, Gastroesophageal Reflux Disease (GERD), heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis and/or esophageal ulcers.

In one exampleembodiment, the MMP-9 associated inflammatory condition is selected from neuropsychiatric illnesses (such as schizophrenia, bipolar mood disorder, multiple sclerosis), neurodegenerative disorders (such as traumatic brain injury, multiple sclerosis, and Alzheimer's disease), cardiovascular diseases, cancer and arthritis.

In a tenth particular exampleaspect, the disclosure invention provides a use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating inflammation of the gastrointestinal tract in a subject.

In one exampleembodiment of the tenth aspect, the disclosure invention provides a use of preventing, ameliorating or treating conditions associated with inflammation of the gastrointestinal tract. In one exampleembodiment, the condition of the gastrointestinal tract is selected from: gastrointestinal inflammatory diseases, gastric ulcers (for example peptic ulcers), gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome (IBS), digestive diseases, Gastroesophageal Reflux Disease (GERD), heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis and/or esophageal ulcers.

In an eleventh particular exampleaspect, the disclosure invention provides a use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating inflammation in a subject.

In another aspect, the disclosure provides a use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating inflammation, optionally wherein the inflammation is associated with the gastrointestinal tract of a subject.

In one exampleembodiment of the eleventh particular aspect, the inflammation is associated with the gastrointestinal tract of a subject. In one exampleembodiment, the inflammation is associated with conditions selected from: gastrointestinal inflammatory diseases, gastric ulcers (for example peptic ulcers), gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome (IBS), digestive diseases, Gastroesophageal Reflux Disease (GERD), heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis and/or esophageal ulcers.

In one exampleembodiment, the inflammation is associated with a condition selected from: , neuropsychiatric illnesses (such as schizophrenia, bipolar mood disorder, multiple sclerosis), neurodegenerative disorders (such as traumatic brain injury, multiple sclerosis, and Alzheimer's disease), cardiovascular diseases, cancer and arthritis.

In a twelfth particular exampleaspect, there is provided a method, use or composition of any one of the above examplesaspects, wherein the composition further comprises a COX-2 inhibitor.

In a thirteenth particular exampleaspect, there is provided a method or use of any one of the above examplesaspects, further comprising co-administration of a COX-2 inhibitor.

Advantages of the above methods and uses may be varied. In some examplesembodiments, the source of 3,6,7-trimethyllumazine is naturally occurring and able to be manufactured on a sustainable basis. 3,6,7-trimethyllumazine is not anticipated to have side effects

and it may be formulated in a wide variety of ways for various methods of administration.

This disclosure ~~invention~~ may also be said broadly to consist in the parts, elements and features referred to or indicated in the specification of the application, individually or collectively, and any or all combinations of any two or more of said parts, elements and features, and where specific integers are mentioned herein which have known equivalents in the art to which this disclosure ~~invention~~ relates, such known equivalents are deemed to be incorporated herein as if individually set forth.

Further examples ~~aspects~~ of the disclosure~~invention~~, which should be considered in all its novel examples~~aspects~~, will become apparent to those skilled in the art upon reading of the following description which provides at least one example of a practical application of the disclosure~~invention~~.

Brief Description of the Drawings

Embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings in which:

Figure 1 is a graph illustrating the fluorescence intensity generated by MMP-9 activity over the course of 10 min.

Figure 2 is a graph illustrating the percentage inhibition of MMP-9 activity from 3,6,7-trimethyllumazine ranging from 2.5–40 µg/ml. Data are shown as mean ± SEM. n=4. ****p<0.0001.

Figure 3 is a graph illustrating the correlation between 3,6,7-trimethyllumazine concentration and MMP-9 inhibition. The IC50 was calculated as 11.5 µg/ml. Data are shown as mean ± SEM. n=4.

Figure 4 is a graph illustrating MMP-9 activity measured by absorbance at 412nm over 120 min.

Figure 5 is a graph illustrating the percentage inhibition by 3,6,7-trimethyllumazine on the activity of MMP-9 (n=5, 2 reciprocal replicates each)

Figure 6 is a graph illustrating that there is no significant interaction between 3,6,7-trimethyllumazine and the chromogenic substrate (A) or the reaction product (B) over the course of 20 min.

Figure 7 shows a typical gelatin gel zymography showing gels incubated in normal developing buffer (column 3-5), 3,6,7-trimethyllumazine supplemented buffer

Claims:

1. ~~A method of preventing, ameliorating or treating an MMP-9 associated condition in a subject, comprising administering to a subject in need thereof~~ Use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating an MMP-9 associated condition.

2. The use of claim 1 wherein the MMP-9 associated condition is an inflammatory condition, optionally wherein the MMP-9 associated inflammatory condition is associated with inflammation of the gastrointestinal tract.

~~2.~~3. The ~~method~~ use of claim 1 or 2 wherein the MMP-9 associated condition is selected from gastrointestinal inflammatory diseases, gastric ulcers, peptic ulcers, gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome, digestive diseases, Gastroesophageal Reflux Disease, heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis, esophageal ulcers, neuropsychiatric illnesses, schizophrenia, bipolar mood disorder, multiple sclerosis, neurodegenerative disorders, traumatic brain injury, ~~multiple sclerosis,~~ Alzheimer's disease, cardiovascular diseases, cancer and arthritis.

~~3. A method of preventing, ameliorating or treating an MMP-9 associated inflammatory condition in a subject, comprising administering to a subject in need thereof a composition comprising 3,6,7-trimethyllumazine.~~

~~4. The method of claim 3 wherein the MMP-9 associated inflammatory condition is associated with inflammation of the gastrointestinal tract.~~

~~5. The method of claim 3 or 4 wherein the MMP-9 associated inflammatory condition is selected from gastrointestinal inflammatory diseases, gastric ulcers, peptic ulcers, gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome, digestive diseases, Gastroesophageal Reflux Disease, heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis, esophageal ulcers, neuropsychiatric illnesses, schizophrenia, bipolar mood disorder, multiple sclerosis, neurodegenerative disorders, traumatic brain injury, multiple sclerosis, Alzheimer's disease, cardiovascular diseases, cancer and arthritis.~~

6.4. ~~A method of preventing, ameliorating or treating inflammation in a subject comprising administering to a subject in need thereof~~ Use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating inflammation, optionally wherein the inflammation is associated with the gastrointestinal tract.

~~7. The method of claim 6 wherein the inflammation is associated with the gastrointestinal tract of a subject.~~

8.5. The ~~method~~ use of claim ~~46 or 7~~ wherein the inflammation is associated with conditions selected from: gastrointestinal inflammatory diseases, gastric ulcers, peptic ulcers, gastritis, MMP-associated inflammatory conditions, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome, digestive diseases, Gastroesophageal Reflux Disease, heartburn, acid reflux, *Helicobacter pylori* infection, mouth ulcers, stomatitis, pharyngitis, gingivitis, esophageal ulcers, neuropsychiatric illnesses, schizophrenia, bipolar mood disorder, multiple sclerosis, neurodegenerative disorders, traumatic brain injury, ~~multiple sclerosis,~~ Alzheimer's disease, cardiovascular diseases, cancer and arthritis.

9.6. The ~~method~~ use of any one of the preceding claims wherein the origin of the 3,6,7-trimethyllumazine is honey, optionally wherein the honey is of a floral origin substantially from Leptospermum, optionally wherein the honey is of a floral origin substantially from: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and/or combinations thereof.

~~10. The method of claim 9 wherein the honey is of a floral origin substantially from: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and/or combinations thereof.~~

11.7. The ~~method~~ use of any one of claims 1 to ~~58~~ wherein the origin of the 3,6,7-trimethyllumazine is nectar, roots, fruit, seeds, bark, oil, leaves, wood, stems or other plant material from *Leptospermum*, optionally wherein the origin of the 3,6,7-trimethyllumazine is nectar, roots, fruit, seeds, bark, oil, leaves, wood, stems or other plant material from a plant selected from: *Leptospermum scoparium,*

Leptospermum polygalifolium, Leptospermum subtenue, and/or combinations thereof.

12. The method of claim 11 wherein the origin of the 3,6,7-trimethyllumazine is nectar, roots, fruit, seeds, bark, oil, leaves, wood, stems or other plant material from a plant selected from: *Leptospermum scoparium, Leptospermum polygalifolium, Leptospermum subtenue*, and/or combinations thereof.

13.8. The method use of any one of claims 1 to 58 wherein the 3,6,7-trimethyllumazine is synthetic.

14.9. The method use of any one of claims 1 to 610 wherein the composition comprising 3,6,7-trimethyllumazine comprises honey or a honey extract.

15.10. The method use of any one of the preceding claims wherein the composition comprises a therapeutically effective amount of 3,6,7-trimethyllumazine.

16.11. The method use of any one of the preceding claims wherein the composition comprises:

- from about 2.5 µg/mL to about 1000 µg/mL 3,6,7-trimethyllumazine; or
- from about 2.5 µg/mL to about 80 µg/mL 3,6,7-trimethyllumazine; or
- about 2.5 µg/mL, about 5 µg/mL, about 10 µg/mL, about 20 µg/mL, about 40 µg/mL, about 50 µg/mL, about 60 µg/mL, about 70 µg/mL or about 80 µg/mL 3,6,7-trimethyllumazine.

17. The method of any one of the preceding claims wherein the composition comprises from about 2.5 µg/mL to about 80 µg/mL 3,6,7-trimethyllumazine.

18. The method of any one of the preceding claims wherein the composition comprises about 2.5 µg/mL, about 5 µg/mL, about 10 µg/mL, about 20 µg/mL, about 40 µg/mL, about 50 µg/mL, about 60 µg/mL, about 70 µg/mL or about 80 µg/mL 3,6,7-trimethyllumazine.

19.12. The method use of any one of claims 1 to 1014 wherein the composition comprises:

- from about 5 mg/kg to about 3000 mg/kg 3,6,7-trimethyllumazine; or
- from about 5 mg/kg to about 80 mg/kg 3,6,7-trimethyllumazine; or
- about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg or about 80 mg/kg of 3,6,7-trimethyllumazine.

~~20. The method of any one of claims 1 to 15 and 18 wherein the composition comprises from about 5 mg/kg to about 80 mg/kg 3,6,7-trimethyllumazine.~~

~~21. The method of claim 120 wherein the composition comprises about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg or about 80 mg/kg of 3,6,7-trimethyllumazine.~~

~~22.~~13. The ~~method~~ use of any one of the preceding claims wherein the composition comprising 3,6,7-trimethyllumazine is formulated as a liquid formulation, fast moving consumer goods, capsule, tablet, chewable tablets, gels, lotions, powders, suppository, cosmetic formulations, intravenous preparations, intramuscular preparations, subcutaneous preparations, solution, food, beverage, dietary supplement or sprays.

~~23.~~14. The ~~method~~ use of any one of claims 1 to 11~~18~~ wherein the composition comprising 3,6,7-trimethyllumazine has a standardised concentration of 3,6,7-trimethyllumazine obtained by:

- selecting a first composition with a known concentration of 3,6,7-trimethyllumazine;
- selecting at least one further composition with a known concentration of 3,6,7-trimethyllumazine;
- combining the first composition with the second composition to obtain a composition with a standardised 3,6,7-trimethyllumazine concentration of from about 5 to about 3000 mg/kg.

~~24.~~15. The ~~method~~ use of any one of claims 1 to 11~~18~~ wherein the composition comprising 3,6,7-trimethyllumazine has a standardised concentration of 3,6,7-

trimethyllumazine obtained by:

- selecting a first composition with a known concentration of 3,6,7-trimethyllumazine;
- combining the selected first composition with one or more of:
  - synthetic 3,6,7-trimethyllumazine;
  - isolated 3,6,7-trimethyllumazine;
  - a honey extract comprising 3,6,7-trimethyllumazine; and/or
  - 3,6,7-trimethyllumazine derived directly from a plant of the genus *Leptospermum*;

to form a composition with a standardised 3,6,7-trimethyllumazine concentration of from about 5 mg/kg to about 3000 mg/kg.

~~25.~~16. A method of making a composition with anti-inflammatory and/or MMP-9 inhibitory activity comprising:

a. testing a first composition comprising honey for 3,6,7-trimethyllumazine concentration;
b. testing at least one further composition comprising honey for 3,6,7-trimethyllumazine concentration;
c. selecting a composition comprising honey with a 3,6,7-trimethyllumazine concentration greater than about 5 mg/kg;
d. selecting at least one further composition comprising honey with a 3,6,7-trimethyllumazine concentration greater than from about 5 mg/kg 3,6,7-trimethyllumazine;
e. combining the selected composition comprising honey to form a honey composition with a 3,6,7-trimethyllumazine concentration of at least from about 5 to about 80 mg/kg,

optionally wherein the composition comprising honey is selected if it has a concentration of 3,6,7-trimethyllumazine greater than about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg or about 80 mg/kg.

~~26. The method of claim 24 wherein composition comprising honey is selected if it has a concentration of 3,6,7-trimethyllumazine greater than about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 70 mg/kg or about 80 mg/kg.~~

~~27.~~17. A method of identifying a composition as having anti-inflammatory and/or MMP-9 inhibitory activity comprising:

a. testing a composition for 3,6,7-trimethyllumazine concentration; and

i. identifying the composition as having anti-inflammatory and/or MMP-9 inhibitory activity if it contains a 3,6,7-trimethyllumazine concentration greater than from about 5 mg/kg; or

ii. identifying the composition as not having anti-inflammatory and/or MMP-9 inhibitory activity if it contains a 3,6,7-trimethyllumazine concentration lower than from about 5 mg/kg,

optionally wherein the composition comprises honey.

~~28. The method of claim 27 wherein the composition comprises honey.~~

~~29. A composition comprising 3,6,7-trimethyllumazine for use in any one of the methods as claimed in claims 1 to 24.~~

~~30. Use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating an MMP-9 associated conditions in a subject.~~

~~31. Use of a composition comprising 3,6,7-trimethyllumazine in the manufacture of a medicament for preventing, ameliorating or treating inflammation.~~

18. The use of claim 1 or 4 wherein:

a. the composition comprising 3,6,7-trimethyllumazine comprises a honey extract comprising a concentration of 3,6,7-trimethyllumazine that is higher than the concentration of 3,6,7-trimethyllumazine found naturally occurring in the honey from which the extract was derived;

b. the composition comprising 3,6,7-trimethyllumazine comprises synthetic 3,6,7-trimethyllumazine and/or 3,6,7-trimethyllumazine isolated from honey; and/or

c. the composition comprising 3,6,7-trimethyllumazine has a standardised concentration of 3,6,7-trimethyllumazine obtained by:

• selecting a first composition with a known concentration of 3,6,7-trimethyllumazine;

• selecting at least one further composition with a known concentration of 3,6,7-trimethyllumazine;

- combining the first composition with the at least one further composition to obtain a composition with a standardised 3,6,7-trimethyllumazine concentration of from about 5 to about 3000 mg/kg.